A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site

Alistar Gordon MacDonald, M. C. Nicolson, Leslie Samuel, A. W. Hutcheon, Fazle Ahmed

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Carcinoma of unknown primary site remains a common clinical diagnosis. accounting for between 5 and 10% of all cancer patients. Numerous combination chemotherapy regimens have been used in the management of carcinoma of unknown primary site, resulting in response rates of 0-48%. We present the results of a single centre phase II study of the use of the combination of mitomycin C (7 m m(-2) on day 1 of cycles 1, 3 and 5) cisplatin (60 mg m(-2) on day 1) and continuous infusion 5-fluorouracil (300 mg m(-2) daily), MCF, delivered as a 21-day cycle, in patients with carcinoma of unknown primary site. Thirty-one patients with a diagnosis of carcinoma of unknown primary site were treated in Aberdeen Royal Infirmary between 1997 and 2001 with MCF. In total, 136 cycles of MCF were delivered (median of 5 cycles per patient), Toxicity was acceptable, with 1958 grade 3 or 4 neutropenia, 16% grade 3 or 4 thrombocytopenia and 13% grade 3 or 4 nausea and vomiting. No cases of neutropenic sepsis were seen and there, were no treatment-related deaths, however, six patients developed thrombotic complications. The over-all response rate was 27% (CR 3% PR 21396). Median time to progression was 3.4 months (95% CI 1.1.-5.6 months) and median overall survival was 7.7 months (95% CI 5.7-9.8 months). Survival at I year was 28%, and at 2,ears, 10% MCF is a tolerable regimen with comparable toxicity, response rates and survival data to most platinum-based combination chemotherapy regimens in use for this devastating disease. (C) 2002 Cancer Research UK.

Original languageEnglish
Pages (from-to)1238-1242
Number of pages4
JournalBritish Journal of Cancer
Volume86
Issue number8
DOIs
Publication statusPublished - 2002

Keywords

  • MCF
  • adenocarcinoma
  • carcinoma of unknown primary site
  • METASTATIC ADENOCARCINOMA
  • CHEMOTHERAPY
  • CARBOPLATIN
  • ORIGIN
  • CANCER
  • TRIAL
  • DOXORUBICIN
  • PACLITAXEL
  • ETOPOSIDE
  • CYCLOPHOSPHAMIDE

Cite this

A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site. / MacDonald, Alistar Gordon; Nicolson, M. C.; Samuel, Leslie; Hutcheon, A. W.; Ahmed, Fazle.

In: British Journal of Cancer, Vol. 86, No. 8, 2002, p. 1238-1242.

Research output: Contribution to journalArticle

@article{10d0623160194372bd9a7a7e12f4d436,
title = "A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site",
abstract = "Carcinoma of unknown primary site remains a common clinical diagnosis. accounting for between 5 and 10{\%} of all cancer patients. Numerous combination chemotherapy regimens have been used in the management of carcinoma of unknown primary site, resulting in response rates of 0-48{\%}. We present the results of a single centre phase II study of the use of the combination of mitomycin C (7 m m(-2) on day 1 of cycles 1, 3 and 5) cisplatin (60 mg m(-2) on day 1) and continuous infusion 5-fluorouracil (300 mg m(-2) daily), MCF, delivered as a 21-day cycle, in patients with carcinoma of unknown primary site. Thirty-one patients with a diagnosis of carcinoma of unknown primary site were treated in Aberdeen Royal Infirmary between 1997 and 2001 with MCF. In total, 136 cycles of MCF were delivered (median of 5 cycles per patient), Toxicity was acceptable, with 1958 grade 3 or 4 neutropenia, 16{\%} grade 3 or 4 thrombocytopenia and 13{\%} grade 3 or 4 nausea and vomiting. No cases of neutropenic sepsis were seen and there, were no treatment-related deaths, however, six patients developed thrombotic complications. The over-all response rate was 27{\%} (CR 3{\%} PR 21396). Median time to progression was 3.4 months (95{\%} CI 1.1.-5.6 months) and median overall survival was 7.7 months (95{\%} CI 5.7-9.8 months). Survival at I year was 28{\%}, and at 2,ears, 10{\%} MCF is a tolerable regimen with comparable toxicity, response rates and survival data to most platinum-based combination chemotherapy regimens in use for this devastating disease. (C) 2002 Cancer Research UK.",
keywords = "MCF, adenocarcinoma, carcinoma of unknown primary site, METASTATIC ADENOCARCINOMA, CHEMOTHERAPY, CARBOPLATIN, ORIGIN, CANCER, TRIAL, DOXORUBICIN, PACLITAXEL, ETOPOSIDE, CYCLOPHOSPHAMIDE",
author = "MacDonald, {Alistar Gordon} and Nicolson, {M. C.} and Leslie Samuel and Hutcheon, {A. W.} and Fazle Ahmed",
year = "2002",
doi = "10.1038/sj.bjc.6600258",
language = "English",
volume = "86",
pages = "1238--1242",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site

AU - MacDonald, Alistar Gordon

AU - Nicolson, M. C.

AU - Samuel, Leslie

AU - Hutcheon, A. W.

AU - Ahmed, Fazle

PY - 2002

Y1 - 2002

N2 - Carcinoma of unknown primary site remains a common clinical diagnosis. accounting for between 5 and 10% of all cancer patients. Numerous combination chemotherapy regimens have been used in the management of carcinoma of unknown primary site, resulting in response rates of 0-48%. We present the results of a single centre phase II study of the use of the combination of mitomycin C (7 m m(-2) on day 1 of cycles 1, 3 and 5) cisplatin (60 mg m(-2) on day 1) and continuous infusion 5-fluorouracil (300 mg m(-2) daily), MCF, delivered as a 21-day cycle, in patients with carcinoma of unknown primary site. Thirty-one patients with a diagnosis of carcinoma of unknown primary site were treated in Aberdeen Royal Infirmary between 1997 and 2001 with MCF. In total, 136 cycles of MCF were delivered (median of 5 cycles per patient), Toxicity was acceptable, with 1958 grade 3 or 4 neutropenia, 16% grade 3 or 4 thrombocytopenia and 13% grade 3 or 4 nausea and vomiting. No cases of neutropenic sepsis were seen and there, were no treatment-related deaths, however, six patients developed thrombotic complications. The over-all response rate was 27% (CR 3% PR 21396). Median time to progression was 3.4 months (95% CI 1.1.-5.6 months) and median overall survival was 7.7 months (95% CI 5.7-9.8 months). Survival at I year was 28%, and at 2,ears, 10% MCF is a tolerable regimen with comparable toxicity, response rates and survival data to most platinum-based combination chemotherapy regimens in use for this devastating disease. (C) 2002 Cancer Research UK.

AB - Carcinoma of unknown primary site remains a common clinical diagnosis. accounting for between 5 and 10% of all cancer patients. Numerous combination chemotherapy regimens have been used in the management of carcinoma of unknown primary site, resulting in response rates of 0-48%. We present the results of a single centre phase II study of the use of the combination of mitomycin C (7 m m(-2) on day 1 of cycles 1, 3 and 5) cisplatin (60 mg m(-2) on day 1) and continuous infusion 5-fluorouracil (300 mg m(-2) daily), MCF, delivered as a 21-day cycle, in patients with carcinoma of unknown primary site. Thirty-one patients with a diagnosis of carcinoma of unknown primary site were treated in Aberdeen Royal Infirmary between 1997 and 2001 with MCF. In total, 136 cycles of MCF were delivered (median of 5 cycles per patient), Toxicity was acceptable, with 1958 grade 3 or 4 neutropenia, 16% grade 3 or 4 thrombocytopenia and 13% grade 3 or 4 nausea and vomiting. No cases of neutropenic sepsis were seen and there, were no treatment-related deaths, however, six patients developed thrombotic complications. The over-all response rate was 27% (CR 3% PR 21396). Median time to progression was 3.4 months (95% CI 1.1.-5.6 months) and median overall survival was 7.7 months (95% CI 5.7-9.8 months). Survival at I year was 28%, and at 2,ears, 10% MCF is a tolerable regimen with comparable toxicity, response rates and survival data to most platinum-based combination chemotherapy regimens in use for this devastating disease. (C) 2002 Cancer Research UK.

KW - MCF

KW - adenocarcinoma

KW - carcinoma of unknown primary site

KW - METASTATIC ADENOCARCINOMA

KW - CHEMOTHERAPY

KW - CARBOPLATIN

KW - ORIGIN

KW - CANCER

KW - TRIAL

KW - DOXORUBICIN

KW - PACLITAXEL

KW - ETOPOSIDE

KW - CYCLOPHOSPHAMIDE

U2 - 10.1038/sj.bjc.6600258

DO - 10.1038/sj.bjc.6600258

M3 - Article

VL - 86

SP - 1238

EP - 1242

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

ER -